在中国治疗特定类型的肺癌时,HURCHMED的药物ORPATHYSYS得到中国的完全批准。 HUTCHMED's drug ORPATHYS® gets full approval in China for treating specific lung cancer types.

中国医疗管理机构对治疗患有某种非小细胞肺癌的成年人的ORPATHYS(savolitinib)药物进行了全面批准。 HUTCHMED has received full approval from China's medical regulatory body for its drug ORPATHYS® (savolitinib) to treat adults with certain types of non-small cell lung cancer (NSCLC). 现在该药物已批准用于新患者和先前接受治疗的MET外基因14跳转变异患者. The drug is now approved for both new and previously treated patients with MET exon 14 skipping alterations. 批准的依据是第三阶段b临床试验,表明该药物是有效和安全的,具有共同副作用,包括肝功能问题和肿胀。 Approval was based on a Phase IIIb clinical trial showing the drug was effective and safe, with common side effects including liver function issues and swelling. 这项批准解决了这些病人的大量未满足的需要。 This approval addresses a significant unmet need for these patients.